Fushimi N, et al. - In noncritically ill hospitalized patients with type 2 diabetes, researchers ascertained if dulaglutide (DU)-combined conventional insulin therapy was beneficial for glycemic control. Participants in the study were randomized to either basal-plus (BP) therapy, where basal insulin and regular insulin corrective doses were given before meals, or BP+DU therapy, where BP therapy was combined with DU. According to this prospective, randomized-controlled pilot study, BP+DU therapy decreased hyperglycemia and hypoglycemia frequencies and resulted in lower glucose variability. There have been no significant side effects in either group.